Progress of tyrosine kinase inhibitor resistance in chronic myeloid leukemia

VernacularTitle:慢性粒细胞白血病酪氨酸激酶抑制剂耐药的研究进展
Author: Mengqing XIE ¹ ; Mengyuan HAN ; Ruiping HU ; Sujun GAO ; Jingnan SUN
Author Information

1. 吉林大学第一医院血液科，长春　130000
Keywords: Leukemia, myeloid, chronic; Mechanism of drug resistance; ABL kinase region mutation; Next-generation sequencing
From: Journal of Leukemia & Lymphoma 2022;31(6):374-377
CountryChina
Language:Chinese
Abstract: Chronic myeloid leukemia (CML) is a malignant tumor formed by clonal proliferation of bone marrow hematopoietic stem cells. With the improvement of disease awareness and the introduction of new drugs, more than 90% of CML patients can achieve long-term survival. However, a few patients still show drug resistance. This article reviews the mechanism of drug resistance in CML patients treated with tyrosine kinase inhibitor (TKI) and the characteristics of ABL kinase region mutation.